New York attorney John MacGregor’s journey into pro bono work became deeply personal when his son was diagnosed with Dravet syndrome, a severe form of epilepsy. This diagnosis marked the beginning of an arduous journey for the MacGregor family, as they navigated the complexities of a rare disease that affects about one in every 15,550 children. MacGregor, a litigation partner at Cahill Gordon & Reindel LLP, found his legal expertise taking an unexpected turn as he began representing a foundation aimed at finding a cure for Dravet syndrome, driven by his firsthand experiences with the barriers to accessing necessary treatments.
Dravet syndrome, caused by a mutation in the SCN1A gene, presents significant challenges due to its debilitating seizures and potential developmental delays. Although there are currently 46 FDA-approved gene therapies, the overall process of bringing a drug to market remains burdensome and expensive. The Orphan Drug Act of 1983 has facilitated the approval of 882 orphan drugs for 392 rare diseases, yet most focus on symptom management rather than underlying genetic causes. Recent advancements in gene editing show promise, but introduce new layers of regulatory and developmental complexity [Law360].
The lengthy drug approval process, costing billions and spanning 10-15 years, underscores the hurdles faced by those advocating for rare diseases. Stoke Therapeutics, for instance, has entered Phase 3 trials with a promising drug for Dravet, and Encoded Therapeutics is advancing into Phase 2. These developments hint at hope for disease-modifying treatments that could transform patients’ lives, offering degrees of independence previously unimaginable.
MacGregor has also extended his advocacy into the courtroom. Filing an amicus brief in a significant case involving Vertex Pharmaceuticals, he challenged a U.S. Department of Health and Human Services advisory opinion that questioned Vertex’s fertility preservation program associated with a gene therapy for sickle cell disease. This case highlights the nuanced legal landscapes biotech companies navigate, emphasizing the tension between innovation and regulatory frameworks.
The Vertex case carries broader implications for the rare disease community, illustrating how legal interpretations can shape drug development incentives. Advocacy groups, including the Dravet Syndrome Foundation, argue that restrictive advisory opinions deter drug development crucial for rare diseases. As gene therapies proliferate, optimal pathways to ensure access and safety continue to evolve, demanding close attention from legal and healthcare professionals alike.
For MacGregor, who balances his professional life with the personal challenges his family faces, this fight is more than legal advocacy—it’s about ensuring that breakthroughs in gene therapy become accessible lifelines for rare disease patients. At Cahill Gordon, the support for attorneys like MacGregor underscores the firm’s commitment to using legal expertise to make meaningful impacts.
As technologies progress, the intricate relationship between legal structures and medical advances will continue to demand collaboration between scientists, advocates, and legal professionals. For families like the MacGregors, each step forward in the courtroom and laboratory holds potential for transforming the future of rare disease treatment.